top of page
Search

A Strategic Victory: The Case of Pfizer and Its Defense Against an Unfair Competition Charge

  • Writer: Héctor Fernández Pineda
    Héctor Fernández Pineda
  • Apr 6
  • 2 min read

Pfizer, S.A. successfully overturned a first-instance judgment for unfair competition and avoided a multimillion-dollar damages award imposed by a Civil Court in Honduras.

Case Overview

On June 21, 2011, the Civil Court of First Instance of Francisco Morazán, Honduras, issued a judgment upholding an ordinary lawsuit for unfair competition and damages. The suit was filed by Laboratorios Stein, S.A. against Pfizer, S.A. (both domiciled in Costa Rica).


The initial ruling ordered Pfizer to pay damages totaling $343,244.56 (approximately L 6,528,511.50).


The Allegations

The legal battle began in November 2005. Laboratorios Stein alleged that Pfizer had engaged in unfair competition by disseminating advertising material that reportedly:

  • Undermined the originality and efficacy of Stein’s product, Atrolip (10 mg), compared to Pfizer’s Lipitor.

  • Was disclosed without authorization, leading to a claimed decline in Stein’s sales and a corresponding increase for Pfizer.


The Defense Strategy

Represented by attorney Héctor Antonio Fernández Pineda, Pfizer rejected these arguments on several key grounds:

  • Scientific Independence: Pfizer clarified that the comparative study in question was conducted by the Laboratory of Biopharmacy and Pharmacokinetics (LABIOFAR) at the University of Costa Rica’s School of Medicine—not by Pfizer itself.

  • Third-Party Dissemination: The study was shared by the Central American Federation of Pharmaceutical Laboratories (FEDEFARMA) to highlight the risks of "copy" products lacking scientific backing for therapeutic equivalence.

  • Market Dynamics: Pfizer argued that any decline in Stein’s sales was likely due to the market entry of other competitors, such as Crestor and Vytorin, rather than unfair practices.


The Turning Point: The Appeal

Despite a wealth of documentary evidence and expert reports, the lower court initially ruled in favor of the plaintiff. Pfizer’s legal team immediately filed an appeal with the Second Civil Court of Appeals of Francisco Morazán.

The appeal challenged the first-instance ruling on two primary fronts:

  1. Lack of Compelling Evidence: There was no direct link establishing Pfizer as the perpetrator of unfair competition.

  2. Unreliable Testimony: The defense successfully challenged the validity of the expert reports and witness testimonies presented by Laboratorios Stein.


The Result

After a thorough review and hearing, the Court of Appeals ruled on October 12, 2011, to uphold the appeal. The court overturned the trial judgment in its entirety, successfully relieving Pfizer, S.A. of the obligation to pay the multimillion-dollar damages award.

Legal Takeaway: This case underscores the importance of challenging "cause and effect" assumptions in unfair competition claims, particularly when third-party scientific studies and broader market shifts are involved.

 
 
 

Comments

bottom of page